

USSN 08/700,565
GRUENBERG
AMENDMENT

61
23. (Twice Amended) The method of claim 22, wherein the Th1 cells with altered cytokine profile are purified.

24. (Twice Amended) The method of claim 22, wherein the Th1 cells with altered cytokine profile are specific for a defined antigen.

25. (Amended) The method of claim 23, wherein the Th1 cells with altered cytokine profile are specific for a defined antigen.

62
28. (Twice Amended) The method of claim 22, wherein the Th1 cells are activated *ex vivo* in the presence of either or both interferon- γ and IL-2, whereby cells differentiate into Th1 cells.

63
155. (Twice amended) A method for generating clinically relevant numbers of Th1 cells for autologous cell therapy, comprising:
(a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;
(b) treating the cells to induce differentiation of mononuclear cells into Th1 cells; and
(c) contacting the resulting differentiated cells with two or more activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of cells for autologous cell therapy are generated, wherein the contacting is effected in the absence of exogenous cytokines.

64
157. (Amended) The method of claim 155, wherein the treating and contacting steps occurs in the absence of exogenous cytokines.

158. (Amended) The method of claim 155, wherein the cells are specific for a selected antigen.